Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 3 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.

Podcast: Prof Robert Brodsky details findings of four of the late-breaking trials at ASH 2017

21 Dec 2017
Professor Robert Brodsky from Johns Hopkins University School of Medicine, and Secretary of ASH, details findings of four of the late-breaking trials: Hokusai VTE-Cancer (dalteparin), Murano (venetoclax), Alcyone (daratumumab), and Hercules (caplacizumab) trials. 
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, Roshini Claire Anthony, 3 days ago
Osimertinib significantly improved progression-free survival (PFS) over standard first-line therapy in the phase III FLAURA trial and experts say it could be the next standard of care (SoC) for advanced non-small cell lung cancer (NSCLC) harbouring EGFR mutation (EGFRm).
17 Feb 2016
A randomized trial has shown that compared to weak opioids, low-dose morphine significantly reduced pain intensity in cancer patients with moderate pain.